Originally published as JCO Early Release 10.1200/JCO.2007.15.8154 on June 2 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by de Lavallade, H. Articles by Marin, D. PubMed PubMed Citation Articles by de Lavallade, H. Articles by Marin, D. Related Articles Related Editorial

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

Hugues de Lavallade, Jane F. Apperley, Jamshid S. Khorashad, Dragana Milojkovic, Alistair G. Reid, Marco Bua, Richard Szydlo, Eduardo Olavarria, Jaspal Kaeda, John M. Goldman, David Marin

From the Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, United Kingdom

Corresponding author: David Marin, MD, Department of Haematology, Imperial College London, Du Cane Rd, London W12 0NN, United Kingdom; e-mail: d.marin{at}imperial.ac.uk

Purpose: Imatinib is remarkably effective in treating newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come from a single multicenter study in which some of the patients were censored for diverse reasons. Here, we report our experience in treating patients at a single institution in a setting where all events were recorded.

Patients and Methods: A total of 204 consecutive adult patients with newly diagnosed CML in CP received imatinib from June 2000 until August 2006. Response (hematologic, cytogenetic, and molecular), progression-free survival (PFS) and survival were evaluated.

Results: At 5 years, cumulative incidences of complete cytogenetic response (CCyR) and major molecular response (MMR) were 82.7% and 50.1%, respectively. Estimated overall survival and PFS were 83.2% and 82.7%, respectively. By 5 years, 25% of patients had discontinued imatinib treatment because of an unsatisfactory response and/or toxicity. The 5-year probability of remaining in major cytogenetic response while still receiving imatinib was 62.7%. Patients achieving a CCyR at 1 year had a better PFS and overall survival than those failing to reach CCyR, but achieving a MMR conferred no further advantage. The identification of a kinase domain mutation was the only factor predicting for loss of CCyR.

Conclusion: Imatinib is highly effective in most patients with CML-CP; patients who respond are likely to live substantially longer than those treated with earlier therapies. Achieving CCyR correlated with PFS and overall survival, but achieving MMR had no further predictive value. However, approximately one third of patients still need better therapy.

published online ahead of print at www.jco.org on June 2, 2008.

Supported by the National Institute for Health Research Biomedical Research Centre Funding Scheme and a grant from the "Fondation de France" (H. de L.).

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Editorial

• Imatinib Therapy for Chronic Myeloid Leukemia: Where Do We Go Now?
  Jorge E. Cortes
  JCO 2008 26: 3308-3309 [Full Text]

This article has been cited by other articles:

				J. E. Cortes Imatinib Therapy for Chronic Myeloid Leukemia: Where Do We Go Now? J. Clin. Oncol., July 10, 2008; 26(20): 3308 - 3309. [Full Text] [PDF]